[go: up one dir, main page]

FR22C1060I1 - Imidazotriazines et imidazopyrimidines utilisees en tant qu'inhibiteurs de kinases - Google Patents

Imidazotriazines et imidazopyrimidines utilisees en tant qu'inhibiteurs de kinases

Info

Publication number
FR22C1060I1
FR22C1060I1 FR22C1060C FR22C1060C FR22C1060I1 FR 22C1060 I1 FR22C1060 I1 FR 22C1060I1 FR 22C1060 C FR22C1060 C FR 22C1060C FR 22C1060 C FR22C1060 C FR 22C1060C FR 22C1060 I1 FR22C1060 I1 FR 22C1060I1
Authority
FR
France
Prior art keywords
imidazotriazines
imidazopyrimidines
kinase inhibitors
kinase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1060C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Holdings Corp
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39166437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1060(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Publication of FR22C1060I1 publication Critical patent/FR22C1060I1/fr
Application granted granted Critical
Publication of FR22C1060I2 publication Critical patent/FR22C1060I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR22C1060C 2006-11-22 2022-12-15 Imidazotriazines et imidazopyrimidines utilisees en tant qu'inhibiteurs de kinases Active FR22C1060I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86084006P 2006-11-22 2006-11-22
US86145906P 2006-11-29 2006-11-29
US95723607P 2007-08-22 2007-08-22
PCT/US2007/085100 WO2008064157A1 (fr) 2006-11-22 2007-11-19 Imidazotriazines et imidazopyrimidines utilisées en tant qu'inhibiteurs de kinases

Publications (2)

Publication Number Publication Date
FR22C1060I1 true FR22C1060I1 (fr) 2023-02-03
FR22C1060I2 FR22C1060I2 (fr) 2023-11-17

Family

ID=39166437

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1060C Active FR22C1060I2 (fr) 2006-11-22 2022-12-15 Imidazotriazines et imidazopyrimidines utilisees en tant qu'inhibiteurs de kinases

Country Status (37)

Country Link
US (7) US7767675B2 (fr)
EP (4) EP3443958A1 (fr)
JP (1) JP5572388B2 (fr)
KR (2) KR101588583B1 (fr)
CN (2) CN103288833B (fr)
AR (1) AR066142A1 (fr)
AU (1) AU2007323725B2 (fr)
BR (1) BRPI0719333A2 (fr)
CA (1) CA2669991C (fr)
CL (1) CL2007003341A1 (fr)
CO (1) CO6210810A2 (fr)
CR (1) CR10841A (fr)
CY (4) CY1116763T1 (fr)
DK (3) DK2099447T3 (fr)
EA (2) EA032254B1 (fr)
EC (1) ECSP099400A (fr)
ES (3) ES2689444T3 (fr)
FR (1) FR22C1060I2 (fr)
GE (1) GEP20125658B (fr)
HK (3) HK1136489A1 (fr)
HR (3) HRP20130106T1 (fr)
HU (2) HUE026659T2 (fr)
IL (4) IL198716A (fr)
LT (1) LT3034075T (fr)
LU (1) LUC00293I2 (fr)
ME (2) ME01507B (fr)
MX (1) MX2009005144A (fr)
MY (2) MY188335A (fr)
NL (1) NL301209I2 (fr)
NO (4) NO346024B1 (fr)
NZ (1) NZ577127A (fr)
PL (3) PL3034075T3 (fr)
PT (3) PT2099447E (fr)
RS (3) RS52677B (fr)
SI (3) SI2497470T1 (fr)
TW (1) TWI429432B (fr)
WO (1) WO2008064157A1 (fr)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2455382T1 (sl) 2005-12-13 2017-03-31 Incyte Holdings Corporation S heteroarilom substituirani pirolo(2,3b)piridini in pirolo(2,3-b)pirimidini kot zaviralci janus kinaze
DK2010493T3 (en) * 2006-04-12 2016-05-02 Merck Sharp & Dohme PYRIDYLAMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS
CA2660836A1 (fr) * 2006-08-07 2008-02-21 Incyte Corporation Utilisation de triazolotriazines en tant qu'inhibiteurs des kinases
RS52677B (en) 2006-11-22 2013-06-28 Incyte Corporation IMIDAZOTRIAZINI I IMIDAZOPIRIMIDINI KAO INHIBITORI KINAZE
MY154969A (en) 2007-06-13 2015-08-28 Incyte Corp Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
AU2008317353B2 (en) * 2007-10-24 2014-08-07 Merck Sharp & Dohme Llc Heterocycle phenyl amide T-type calcium channel antagonists
EA201001365A1 (ru) 2008-02-28 2011-04-29 Новартис Аг ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДУЕМОГО C-МЕТ ТИРОЗИНКИНАЗОЙ
BRPI0912882A2 (pt) * 2008-05-21 2017-05-16 Incyte Corp sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos
WO2010002472A1 (fr) * 2008-07-02 2010-01-07 Ambit Biosciences Corporation Composés modulant les kinases jak et procédés pour les utiliser
FR2933982A1 (fr) * 2008-07-18 2010-01-22 Sanofi Aventis Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
UY32049A (es) * 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
JP5777526B2 (ja) * 2009-02-13 2015-09-09 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 縮合ピリミジン類
JP5775070B2 (ja) 2009-05-22 2015-09-09 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
NZ596374A (en) 2009-05-22 2014-01-31 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
AR077280A1 (es) 2009-06-29 2011-08-17 Incyte Corp Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
IN2012DN01453A (fr) * 2009-08-20 2015-06-05 Novartis Ag
WO2011028685A1 (fr) 2009-09-01 2011-03-10 Incyte Corporation Dérivés hétérocycliques de pyrazol-4-yl-pyrrolo[2,3-d] pyrimidines en tant qu'inhibiteurs de janus kinase
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
ME02211B (me) 2009-12-31 2016-02-20 Hutchison Medipharma Ltd Neki triazolopirazini, njihove kompozicije i postupci njihovog korišćenja
EA025304B1 (ru) 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
SMT202000373T1 (it) 2010-03-10 2020-09-10 Incyte Holdings Corp Piperidin-4-il azetidin derivati come inibitori di jak1
US8518945B2 (en) * 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
EP2558463A1 (fr) 2010-04-14 2013-02-20 Incyte Corporation Dérivés condensés en tant qu'inhibiteurs de i3
US8962596B2 (en) * 2010-04-14 2015-02-24 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases
ES2715611T3 (es) 2010-05-17 2019-06-05 Incozen Therapeutics Pvt Ltd Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas
SG10201910912TA (en) 2010-05-21 2020-01-30 Incyte Corp Topical Formulation for a JAK Inhibitor
WO2012068440A1 (fr) 2010-11-19 2012-05-24 Incyte Corporation Pyrrolopyridines et pyrrolopyrimidines à substitution hétérocyclique utilisées en tant qu'inhibiteurs des jak
EA026201B1 (ru) 2010-11-19 2017-03-31 Инсайт Холдингс Корпорейшн Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak
EP2655374B1 (fr) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(phényl substitué)éthyl)-9h-purin-6-amines en tant qu'inhibiteurs de pi3k
WO2012105594A1 (fr) 2011-02-01 2012-08-09 協和発酵キリン株式会社 Dérivé hétérocylique à cycles fusionnés
WO2012125629A1 (fr) 2011-03-14 2012-09-20 Incyte Corporation Dérivés diamino-pyrimidines et diamino-pyridines substituées en tant qu'inhibiteurs de pi3k
WO2012135009A1 (fr) 2011-03-25 2012-10-04 Incyte Corporation Dérivés de pyrimidine-4,6-diamine en tant qu'inhibiteurs de pi3k
BR112013032720A2 (pt) 2011-06-20 2016-09-13 Incyte Corp "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados"
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
SMT202100288T1 (it) 2011-09-02 2021-07-12 Incyte Holdings Corp Eterociclilammine come inibitori di pi3k
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
ES2691650T3 (es) 2011-09-15 2018-11-28 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
CN103030654A (zh) * 2011-10-09 2013-04-10 济南赛文医药技术有限公司 一种小分子c-Met蛋白激酶抑制剂
CN103987713A (zh) * 2011-10-12 2014-08-13 阵列生物制药公司 5,7-取代的咪唑并[1,2-c]嘧啶
EP3750544B1 (fr) 2011-11-30 2025-03-05 Emory University Inhibiteurs jak destinées à la prévention ou au traitement d'une maladie causé par une coronaviridée
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CN104244982A (zh) 2012-04-03 2014-12-24 诺华股份有限公司 酪氨酸激酶抑制剂组合及其用途
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
WO2013173720A1 (fr) 2012-05-18 2013-11-21 Incyte Corporation Dérivés de pyrrolopyridine et de pyrrolopyrimidine substitués par un pipéridinylcyclobutyle à titre d'inhibiteurs jak
ME03300B (fr) 2012-06-13 2019-07-20 Incyte Holdings Corp Composés tricycliques substitués servant d'inhibiteurs des fgfr
WO2014028566A1 (fr) * 2012-08-16 2014-02-20 Novartis Ag Combinaison d'un inhibiteur pi3k et d'un inhibiteur c-met
IL291391B (en) 2012-11-15 2022-11-01 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EA201891157A1 (ru) 2013-03-06 2019-02-28 Инсайт Холдингс Корпорейшн Способы и промежуточные соединения при получении ингибитора jak
CN107312009B (zh) * 2013-04-17 2022-09-20 上海医药集团股份有限公司 喹啉类化合物、其制备方法、中间体、药物组合物和应用
WO2014174478A1 (fr) 2013-04-26 2014-10-30 Novartis Ag Combinaisons pharmaceutiques d'un inhibiteur de la pkc et d'un inhibiteur du récepteur tyrosine-kinase c-met
SG10201801069QA (en) 2013-08-07 2018-03-28 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
GB201321732D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321736D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2015123408A1 (fr) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
CN111454188A (zh) 2014-02-13 2020-07-28 因赛特公司 作为lsd1抑制剂的环丙胺
EA201691594A1 (ru) 2014-02-13 2017-02-28 Инсайт Корпорейшн Циклопропиламины в качестве ингибиторов lsd1
ME03558B (fr) 2014-03-14 2020-07-20 Novartis Ag Molécules d'anticorps anti-lag-3 et leurs utilisations
JP6752715B2 (ja) 2014-03-26 2020-09-09 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 組合せ
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
WO2016007727A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016007722A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
WO2016007736A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines en tant qu'inhibiteurs de lsd1
EA202191301A1 (ru) * 2014-07-25 2021-11-30 Новартис Аг СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
WO2016011658A1 (fr) * 2014-07-25 2016-01-28 Novartis Ag Polythérapie
MX2017001461A (es) 2014-07-31 2017-05-11 Novartis Ag Terapia de combinacion.
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
EP3200775B1 (fr) 2014-10-03 2019-11-20 Novartis AG Polythérapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
UA121669C2 (uk) * 2015-02-20 2020-07-10 Інсайт Корпорейшн Біциклічні гетероцикли як інгібітори fgfr
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
KR20240132104A (ko) 2015-02-27 2024-09-02 인사이트 홀딩스 코포레이션 Pi3k 억제제의 염 및 이의 제조 공정
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
AU2016243939B2 (en) 2015-04-03 2020-09-03 Incyte Holdings Corporation Heterocyclic compounds as LSD1 inhibitors
CN106715440B (zh) 2015-04-21 2019-02-22 江苏恒瑞医药股份有限公司 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
WO2016183063A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Formes cristallines d'un inhibiteur de pi3k
WO2016183060A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Procédé de synthèse d'un inhibiteur de phospho-inositide 3-kinases
RU2683022C1 (ru) 2015-05-22 2019-03-26 Чонг Кун Данг Фармасьютикал Корп. Производные гетероциклические алкильные соединения в качестве селективных ингибиторов гистондеацетилазы и содержащие их фармацевтические композиции
EP3317301B1 (fr) 2015-07-29 2021-04-07 Novartis AG Polythérapies comprenant des molécules d'anticorps dirigées contre lag-3
EP3316902A1 (fr) 2015-07-29 2018-05-09 Novartis AG Polythérapies comprenant des molécules d'anticorps contre tim -3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3334709B1 (fr) 2015-08-12 2024-12-11 Incyte Holdings Corporation Sels d'un inhibiteur de lsd1
AU2016369623A1 (en) * 2015-12-17 2018-06-28 Novartis Ag Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof
US20180371093A1 (en) 2015-12-17 2018-12-27 Novartis Ag Antibody molecules to pd-1 and uses thereof
UA125463C2 (uk) 2016-01-27 2022-03-16 Універсітет Цюріх ЗАСТОСУВАННЯ МОДУЛЯТОРІВ GABA<sub>A</sub>-РЕЦЕПТОРА ДЛЯ ЛІКУВАННЯ СВЕРБЕЖУ
CR20180516A (es) * 2016-03-28 2019-03-05 Incyte Corp Compuestos de iprrolotriazina como inhibidores de tam
AR109452A1 (es) 2016-04-22 2018-12-12 Incyte Corp Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento
JP7027343B2 (ja) * 2016-05-23 2022-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄｋ８／ｃｄｋ１９阻害剤としての新しいフェニルピラゾリルアセトアミド化合物及び誘導体
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN106496000A (zh) * 2016-10-19 2017-03-15 蚌埠学院 一种3‑氟‑4‑溴‑苯乙酮的合成方法
US10287303B2 (en) 2016-12-22 2019-05-14 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CU24606B1 (es) 2017-06-22 2022-06-06 Novartis Ag Moléculas de anticuerpo que se unen a cd73
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
CN111386273B (zh) 2017-09-27 2024-06-14 因赛特公司 可用作tam抑制剂的吡咯并三嗪衍生物的盐
KR102740831B1 (ko) 2017-11-14 2024-12-11 칠드런'즈 메디컬 센터 코포레이션 신규 이미다조피리미딘 화합물 및 그의 용도
JP7382316B2 (ja) * 2017-11-14 2023-11-16 ザ チルドレンズ メディカル センター コーポレーション ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用
TW201922291A (zh) 2017-11-16 2019-06-16 瑞士商諾華公司 組合療法
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
HRP20220510T1 (hr) 2018-01-30 2022-05-27 Incyte Corporation Postupci za pripravu (1-(3-fluoro-2-(trifluorometil)izonikotinil) piperidin-4-ona)
EP4424328A3 (fr) 2018-03-30 2024-12-04 Incyte Corporation Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
CN110526916B (zh) * 2018-05-23 2021-07-13 海创药业股份有限公司 氘代Capmatinib化合物及其用途
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (fr) 2018-05-31 2019-12-05 Novartis Ag Molécules d'anticorps anti-cd73 et leurs utilisations
SG11202011680YA (en) 2018-06-01 2020-12-30 Incyte Corp Dosing regimen for the treatment of pi3k related disorders
CN108530337B (zh) * 2018-06-25 2020-11-03 南华大学 一种可选择性抑制胃癌细胞的吲哚酰胺类化合物
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CA3118093A1 (fr) * 2018-09-28 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibiteurs a petites molecules de dyrk1/clk et leurs utilisations
MX2021007392A (es) 2018-12-20 2021-08-24 Novartis Ag Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
CR20210336A (es) * 2018-12-20 2021-12-06 Incyte Corp Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
MX2021009763A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
EA202192029A1 (ru) 2019-02-15 2021-10-27 Новартис Аг Замещенные производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
CA3165399A1 (fr) 2019-12-20 2021-06-24 Novartis Ag Utilisations d'anticorps anti-tgf-betas et inhibiteurs de point de controle pour le traitement des maladies proliferatives
WO2021173476A1 (fr) * 2020-02-24 2021-09-02 The Trustees Of Columbia University In The City Of New York Composés, formulations pharmaceutiques et méthodes de traitement du cancer
CN115697343A (zh) 2020-03-06 2023-02-03 因赛特公司 包含axl/mer和pd-1/pd-l1抑制剂的组合疗法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN111825678A (zh) * 2020-06-05 2020-10-27 连庆泉 一种卡马替尼的制备方法
IL298262A (en) 2020-06-23 2023-01-01 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022007752A1 (fr) * 2020-07-06 2022-01-13 苏州晶云药物科技股份有限公司 Nouvelle forme cristalline d'un composé benzamide et de son dichlorhydrate et procédé de préparation correspondant
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3215903A1 (fr) 2021-04-12 2022-10-20 Incyte Corporation Polytherapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
AU2022336415A1 (en) 2021-09-01 2024-01-04 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
CN113896732B (zh) * 2021-10-13 2023-09-12 沈阳红旗制药有限公司 抗癌药物卡马替尼的制备方法及其应用
WO2023249994A1 (fr) * 2022-06-22 2023-12-28 Mayo Foundation For Medical Education And Research Méthodes et matériels pour le traitement du cancer
TW202421146A (zh) 2022-07-08 2024-06-01 瑞典商阿斯特捷利康公司 用於治療癌症的上皮生長因子受體酪胺酸激酶抑制劑與ｈｇｆ受體抑制劑的組合
CN116903627B (zh) * 2023-05-15 2024-01-16 云白药征武科技(上海)有限公司 一种咪唑并三嗪硫代苯甲酰胺衍生物及其制备方法和应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1411859A (en) 1920-12-08 1922-04-04 Marchand Robert Process for preparing hydrate of terpin
US2837520A (en) * 1955-05-26 1958-06-03 Ind Chimica Profarmaco S R L Fluorescent materials on the basis of tetrazoindenes
US4209621A (en) 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
US4405619A (en) 1981-09-02 1983-09-20 Diamond Shamrock Corporation Antiinflammatory substituted-1,2,4-triazolo[4,3-b]-1,2,4-triazines
DE3311753A1 (de) 1983-03-31 1984-10-04 Hoechst Ag, 6230 Frankfurt Substituierte 6-aryl-1,2,4-triazolo(4,3-b)pyridazine - ihre herstellung und verwendung -
JPS6337347A (ja) 1986-08-01 1988-02-18 Fuji Photo Film Co Ltd 直接ポジカラ−画像形成方法
JPS63199347A (ja) 1987-02-14 1988-08-17 Konica Corp 鮮鋭性の向上した高感度ハロゲン化銀写真感光材料
JPS63310891A (ja) 1987-06-12 1988-12-19 Yoshitomi Pharmaceut Ind Ltd 縮合ピリダジン化合物
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
JPH0313934A (ja) 1989-06-12 1991-01-22 Konica Corp ハロゲン化銀写真感光材料
IL96432A0 (en) 1989-11-30 1991-08-16 Schering Ag Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
JP2664264B2 (ja) 1990-02-15 1997-10-15 富士写真フイルム株式会社 ハロゲン化銀写真乳剤及びこれを用いた写真感光材料
FR2662163A1 (fr) 1990-05-16 1991-11-22 Lipha Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant.
JPH04251243A (ja) 1991-01-09 1992-09-07 Konica Corp ハロゲン化銀写真感光材料
FR2671551B1 (fr) 1991-01-15 1993-03-12 Adir Nouveaux composes de structure aryl triazinique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5232618A (en) 1991-09-30 1993-08-03 E. I. Du Pont De Nemours And Company Substantially constant boiling compositions of difluoromethane and trifluoroethane or perfluoroethane
JPH05232618A (ja) 1992-02-21 1993-09-10 Konica Corp ハロゲン化銀写真感光材料
DE4309285A1 (de) 1993-03-23 1994-09-29 Boehringer Ingelheim Kg Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung
NZ502642A (en) * 1997-07-03 2002-06-28 Du Pont Pharm Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
ES2137113B1 (es) 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
DE19734311A1 (de) 1997-08-08 1999-02-11 Bosch Gmbh Robert Anordnung zur Übertragung optischer Signale mit Ersatzschaltungswirkung
JP4251243B2 (ja) 1998-11-26 2009-04-08 株式会社日立メディコ 領域拡張装置
JP4025468B2 (ja) 1999-07-29 2007-12-19 三井化学株式会社 有機電界発光素子
JP2003513977A (ja) 1999-11-10 2003-04-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換２−アリール−３−（ヘテロアリール）−イミダゾ［１，２−α］ピリミジン類および関連薬剤組成物および方法
CA2388593A1 (fr) 1999-11-12 2001-05-17 Neurogen Corporation Composes heteroaromatiques bicycliques et tricycliques
DE10010067A1 (de) * 2000-03-02 2001-09-06 Bayer Ag Neue Imidazotriazinone und ihre Verwendung
AU2000240570A1 (en) * 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
ES2251518T3 (es) 2000-11-10 2006-05-01 MERCK SHARP &amp; DOHME LTD. Derivados de imidazo-triazina como ligandos para receptores gaba.
GB0103926D0 (en) * 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
EP1370559B1 (fr) 2001-03-09 2006-04-19 Pfizer Products Inc. Triazolopyridines, agents anti-inflammatoires
GB0107751D0 (en) 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
CA2448076A1 (fr) 2001-05-24 2002-11-28 Masahiko Hayakawa Derives de 3-quinoleine-2-(1h)-ylideneindoline-2-one
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
WO2003074525A1 (fr) 2002-03-01 2003-09-12 Yamanouchi Pharmaceutical Co., Ltd. Compose heterocyclique azote
AU2003223295A1 (en) 2002-03-19 2003-10-08 Merck And Co., Inc. Process and intermediates to substituted imidazopyrimidines
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles
GB0210127D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
AU2003253188A1 (en) 2002-08-30 2004-03-19 Pfizer Products Inc. Novel processes and intermediates for preparing triazolo-pyridines
US6784297B2 (en) 2002-09-04 2004-08-31 Kopran Limited Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
ATE473980T1 (de) 2002-12-18 2010-07-15 Vertex Pharma Triazolopyridazine als proteinkinase-inhibitoren
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
GB0303910D0 (en) * 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
AP2114A (en) 2003-02-26 2010-03-04 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
EP1640010A1 (fr) 2003-07-01 2006-03-29 Astellas Pharma Inc. Agent d'induction de croissance dans la masse osseuse
CA2529622A1 (fr) 2003-07-02 2005-01-20 Sugen, Inc. Hydrazides d'indolinone utilises en tant qu'inhibiteurs du recepteur c-met
JP2007516180A (ja) 2003-07-02 2007-06-21 スゲン，インコーポレイティド ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
US7037909B2 (en) 2003-07-02 2006-05-02 Sugen, Inc. Tetracyclic compounds as c-Met inhibitors
ATE380816T1 (de) 2003-07-30 2007-12-15 S A L V A T Lab Sa Substituierte imidazopyrimidine zur prävention und behandlung von krebs
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
CA2539726A1 (fr) 2003-09-24 2005-05-06 Vertex Pharmaceuticals Incorporated Compositions d'imidazole utilisees comme inhibiteurs des proteines kinases
WO2005030140A2 (fr) 2003-09-26 2005-04-07 Exelixis, Inc. Modulateurs de c-met et procede d'utilisation
US7144889B2 (en) 2003-10-16 2006-12-05 Hoffman-La Roche Inc. Triarylimidazoles
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
WO2005070891A2 (fr) 2004-01-23 2005-08-04 Amgen Inc Composes et leurs procedes d'utilisation
EP1711495A2 (fr) 2004-01-23 2006-10-18 Amgen Inc. Quinolines, chinazolines, pyridines et pyrimidines et leur utilsation dans le traitement d'inflammation, angiogenèse et le cancer
EP1719756A4 (fr) 2004-02-18 2007-09-26 Banyu Pharma Co Ltd Derive azote de noyau heteroaromatique fusionne
UA89493C2 (uk) * 2004-04-02 2010-02-10 Оси Фармасьютикалз, Инк. 6,6-біциклічні кільцеві заміщені гетеробіциклічні інгібітори протеїнкіназ
US20050277650A1 (en) 2004-04-20 2005-12-15 Sundaram Venkataraman Process for preparing aripirazole hydrate
WO2005113494A2 (fr) 2004-05-07 2005-12-01 Amgen Inc. Modulateurs de proteines kinases et procede d'utilisation
WO2005121125A1 (fr) 2004-06-09 2005-12-22 Pfizer Inc. Composes heteroaryle a liaison ether
AU2005270068B2 (en) 2004-07-02 2012-04-19 Exelixis, Inc. C-Met modulators and method of use
MY139689A (en) * 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
MX2007001127A (es) * 2004-07-27 2007-07-11 Sgx Pharmaceuticals Inc Moduladores de pirrolo-piridina cinasa.
RS51362B (en) 2004-08-26 2011-02-28 Pfizer Inc. ENANTIOMERALLY PURE AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS
AU2005295734A1 (en) 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
JP4935357B2 (ja) * 2004-11-08 2012-05-23 Ｍｓｄ株式会社 新規縮環イミダゾール誘導体
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
CN101137412B (zh) 2005-01-13 2012-11-07 布里斯托尔-迈尔斯·斯奎布公司 用作凝血因子XIa抑制剂的取代的二芳基化合物
WO2006124354A2 (fr) * 2005-05-12 2006-11-23 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
US20080214562A1 (en) 2005-07-11 2008-09-04 Kristjan Gudmundsson Chemical Compounds
WO2007015866A2 (fr) * 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibiteurs de la p38 kinase et procédés de traitement d’affections inflammatoires
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
WO2007025090A2 (fr) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibiteurs de kinase mapk/erk
WO2007064797A2 (fr) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de c-met et leurs utilisations
UA98297C2 (en) 2005-12-21 2012-05-10 Янссен Фармацевтика, Н.В. Triazolopyridazines as tyrosine kinase modulators
ES2761180T3 (es) 2005-12-23 2020-05-19 Ariad Pharma Inc Compuestos bicíclicos de heteroarilo
WO2007096764A2 (fr) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Dérivés d'hétéroaryles bicycliques en tant que modulateurs des récepteurs cannabinoïdes
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
CA2660836A1 (fr) 2006-08-07 2008-02-21 Incyte Corporation Utilisation de triazolotriazines en tant qu'inhibiteurs des kinases
EP2081937B1 (fr) 2006-10-23 2012-09-12 SGX Pharmaceuticals, Inc. Modulateurs de protéines kinases à base de triazolopyridazines
SG176461A1 (en) 2006-11-06 2011-12-29 Supergen Inc Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
RS52677B (en) * 2006-11-22 2013-06-28 Incyte Corporation IMIDAZOTRIAZINI I IMIDAZOPIRIMIDINI KAO INHIBITORI KINAZE
EP2162132A4 (fr) 2007-05-21 2013-01-16 Sgx Pharmaceuticals Inc Modulateurs de kinase hétérocycliques
BRPI0912882A2 (pt) 2008-05-21 2017-05-16 Incyte Corp sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos
EA025304B1 (ru) 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
CA2832994A1 (fr) 2011-05-06 2012-11-15 Takasago International Corporation Complexe ruthenium-diamine et procede de production d'un compose optiquement actif

Also Published As

Publication number Publication date
KR20150014476A (ko) 2015-02-06
ES2398843T3 (es) 2013-03-22
CY2022037I2 (el) 2023-03-24
HK1225978B (zh) 2017-09-22
CY1116763T1 (el) 2017-03-15
ME02372B (me) 2016-06-20
EA201691862A2 (ru) 2017-09-29
US20110136781A1 (en) 2011-06-09
SI3034075T1 (sl) 2018-12-31
RS57741B1 (sr) 2018-12-31
EA032254B1 (ru) 2019-04-30
KR101532256B1 (ko) 2015-06-29
NO2022057I1 (no) 2022-12-13
US11261191B2 (en) 2022-03-01
PL3034075T3 (pl) 2019-03-29
NL301209I1 (nl) 2022-12-21
HRP20160077T1 (hr) 2016-02-12
EA200970501A1 (ru) 2009-12-30
US20200317680A1 (en) 2020-10-08
PL2497470T3 (pl) 2016-04-29
AU2007323725B2 (en) 2014-02-20
MY188335A (en) 2021-11-30
EP2497470B1 (fr) 2015-10-28
PT3034075T (pt) 2018-11-05
IL276928B (en) 2022-03-01
US20230002392A1 (en) 2023-01-05
GEP20125658B (en) 2012-10-10
BRPI0719333A2 (pt) 2014-02-04
RS54510B1 (en) 2016-06-30
PL2099447T3 (pl) 2013-06-28
CN101641093B (zh) 2013-05-29
IL198716A (en) 2016-03-31
LUC00293I2 (fr) 2024-10-04
HK1175700A1 (zh) 2013-07-12
IL284889B2 (en) 2023-05-01
PT2099447E (pt) 2013-02-27
US20130324515A1 (en) 2013-12-05
MY188338A (en) 2021-11-30
EP2099447A1 (fr) 2009-09-16
NO344399B1 (no) 2019-11-25
PT2497470E (pt) 2016-02-22
LT3034075T (lt) 2018-11-26
AU2007323725A1 (en) 2008-05-29
NZ577127A (en) 2012-03-30
IL284889B1 (en) 2023-01-01
US10738052B2 (en) 2020-08-11
US7767675B2 (en) 2010-08-03
CR10841A (es) 2009-06-30
CY1121021T1 (el) 2020-05-29
CY1117108T1 (el) 2017-04-05
ES2560435T3 (es) 2016-02-19
EP3034075A1 (fr) 2016-06-22
US8461330B2 (en) 2013-06-11
CY2022037I1 (el) 2023-01-27
IL284889A (en) 2021-08-31
TW200835481A (en) 2008-09-01
TWI429432B (zh) 2014-03-11
IL244244B (en) 2020-09-30
EP3443958A1 (fr) 2019-02-20
CN103288833B (zh) 2018-01-12
HUE026659T2 (en) 2016-07-28
JP2010510319A (ja) 2010-04-02
NO344864B1 (no) 2020-06-02
NO20200077A1 (no) 2009-07-28
EA201691862A3 (ru) 2017-12-29
SI2099447T1 (sl) 2013-03-29
DK2497470T3 (en) 2015-12-07
EP2497470B8 (fr) 2015-12-02
SI2497470T1 (sl) 2016-02-29
EA026126B1 (ru) 2017-03-31
EP2099447B1 (fr) 2012-11-07
KR101588583B1 (ko) 2016-01-28
NO346024B1 (no) 2022-01-03
ES2689444T3 (es) 2018-11-14
HRP20181622T1 (hr) 2018-12-14
NO20091924L (no) 2009-07-28
WO2008064157A1 (fr) 2008-05-29
IL198716A0 (en) 2010-02-17
MX2009005144A (es) 2009-05-27
US12084449B2 (en) 2024-09-10
HUS2200052I1 (hu) 2023-01-28
AR066142A1 (es) 2009-07-29
US20180282340A1 (en) 2018-10-04
US20080167287A1 (en) 2008-07-10
NL301209I2 (nl) 2023-01-24
CN101641093A (zh) 2010-02-03
EP2497470A1 (fr) 2012-09-12
ME01507B (me) 2014-04-20
FR22C1060I2 (fr) 2023-11-17
DK2099447T3 (da) 2013-02-18
DK3034075T3 (en) 2018-10-22
RS52677B (en) 2013-06-28
US9944645B2 (en) 2018-04-17
ECSP099400A (es) 2009-07-31
HK1136489A1 (en) 2010-07-02
HRP20130106T1 (hr) 2013-03-31
CA2669991C (fr) 2016-01-26
EP3034075B1 (fr) 2018-07-25
CO6210810A2 (es) 2010-10-20
CA2669991A1 (fr) 2008-05-29
CL2007003341A1 (es) 2008-04-18
KR20090094299A (ko) 2009-09-04
JP5572388B2 (ja) 2014-08-13
NO20190709A1 (no) 2009-07-28
US20160326178A1 (en) 2016-11-10
CN103288833A (zh) 2013-09-11
IL244244A0 (en) 2016-04-21
IL276928A (en) 2020-10-29

Similar Documents

Publication Publication Date Title
FR22C1060I2 (fr) Imidazotriazines et imidazopyrimidines utilisees en tant qu&#39;inhibiteurs de kinases
CY2015016I1 (el) Αναστολεις της κινασης τυροσινης του bruton
IL266741A (en) Broton tyrosine kinase inhibitors
CY2015043I2 (el) Ενωσεις και συνθεσεις ως αναστολεις των πρωτεϊνικων κινασων
CR10755A (es) Compounds and compositions as protein kinase inhibitors
ZA200901593B (en) Pyrimidines derivatives and their use as kinase inhibitors
IL192640A0 (en) Inhibitors of tyrosine kinases and pharmaceutical compositions containing the same
EP1893607A4 (fr) Inhibiteurs de kinases checkpoint
EP2231143A4 (fr) Inhibiteurs de janus kinases
CR10639A (es) Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors
SMAP200800048A (it) Derivati pirimidinici utilizzati come inibitori dip13-chinasi
ZA201004055B (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
SMP200800022B (it) Benzimidazoli sostituiti come inibitori delle chinasi
DE602007008837D1 (de) Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
EP2004654A4 (fr) Antagonistes de la kinase
BRPI0915231A2 (pt) compostos inibidores de quinase e métodos de uso
BRPI0716781A2 (pt) Inibidores da quinase
ATE493403T1 (de) Kinaseinhibitoren
ZA200709000B (en) Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
EP2200612A4 (fr) Inhibiteurs de janus kinases
DOP2007000082A (es) Inhibidores de quinasas de puntos de control
ATE520664T1 (de) Tyrosinkinase-hemmer
EP1951252A4 (fr) Inhibiteurs des tyrosine kinases
BRPI0719883A2 (pt) Inibidores de quinase
DE602006019301D1 (de) Kinaseinhibitoren